ESTRO 2024 - Abstract Book

S1655

Clinical - Lung

ESTRO 2024

1. Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, et al. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology. 2020 Nov;25:61 – 6.

2. Horne et al. CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in NSCLC. Lung Cancer. 2023;178(1):S86 – 7.

3. Giuranno L, Ient J, De Ruysscher D, Vooijs MA. Radiation-Induced Lung Injury (RILI). Front Oncol. 2019 Sep 6;9:877.

1263

Poster Discussion

Prospective clinical trial of biomarkers of cardiac toxicity in thoracic radiotherapy (18/NW/0706)

Kathryn Banfill 1,2 , Matthias Schmitt 3 , Fei Sun 4 , Joanne Riley 3 , Alan McWilliam 2,1 , Kevin Franks 4 , Ahmed Salem 5,2 , Neil Bayman 1 , Clara Chan 1 , Joanne Coote 1 , Margaret Harris 1 , Laura Pemberton 1 , Hamid Sheikh 1 , David Kenneth Woolf 1 , Marcel vanHerk 2 , Corinne Faivre-Finn 2,1 1 The Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom. 2 The University of Manchester, Cancer Sciences, Manchester, United Kingdom. 3 Manchester University NHS Foundation Trust, Cardiology, Manchester, United Kingdom. 4 Leeds Teaching Hospitals NHS Trust, Oncology, Leeds, United Kingdom. 5 Hashemite University, Faculty of Medicine, Zarqa, Jordan

Purpose/Objective:

Heart radiation dose is associated with survival and cardiac events (CE) following radiotherapy for lung cancer however, the mechanisms of damage are largely unknown [1]. High sensitivity cardiac troponin I (hsTnI) and N terminal pro-B-type natriuretic peptide (NT-proBNP) are established blood biomarkers of cardiac damage [2]. Heart irradiation also affects lymphoid and myeloid cells [3]. Cardiac computed tomography (CCT) is a non-invasive method of assessing coronary artery disease. Echocardiography assesses cardiac structure and function. Here we describe the results of a prospective cohort study of cardiac blood and imaging biomarkers in patients undergoing curative-intent radiotherapy for lung cancer.

Material/Methods:

Patients were eligible for inclusion in the trial if they had a histological or clinical diagnosis of stage 1-3 lung cancer and had curative intent radiotherapy (total dose >45Gy). Ethical approval was granted by regional ethics committee (18/NW/0706). Radiotherapy with >5Gy/fraction was defined as stereotactic ablative body radiotherapy (SABR). Blood samples were collected for HsTnI, NT-proBNP, cholesterol, creatinine and white cell count at three timepoints: within 14 days prior to starting radiotherapy; at the end of radiotherapy (+/- 7days) and 4-9 months after the end of radiotherapy.